AQST Q3 2018 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$424M

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M-51.1% YoY

Gross Profit

$8M57.9% margin

Operating Income

-$9M-69.4% margin

Net Income

-$15M-113.3% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$90M

Total Liabilities

$67M

Stockholders' Equity

$23M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$27M	-51.1%
Gross Profit	$8M	$22M	-65.5%
Operating Income	-$9M	$10M	-188.3%
Net Income	-$15M	$8M	-277.9%

Revenue Segments

Manufacture and Supply Revenue

$9M68%

License and Royalty Revenue

$3M25%

Co-Development and Research Fees

$907,0007%

Geographic Segments

United States

$12M100%